SPE2DB22D1200 - PRIME VENDOR PHARM BRANCH-PHILADELPHIA
Federal Contract Award Search » IDC Award
This IDC contract for Pharmaceuticals > Pharmaceutical Products was awarded in FY2022 on Mar 23, 2022 to Cencora by DLA Medical Directorate. There have been $34.7M in obligations to date with a ceiling value of $1,000M, showing a 3% burn rate so far on the contract. The contract was not competed under any preference program with 4 offers received. We expect a 3 year duration with ultimate completion date of Dec 30, 2025.
Cencora is a contractor located in PA, doing primarily Pharmaceuticals > Pharmaceutical Products work for Defense. The company receives $2.2B annually in federal awards (as of FY2020). Also, they have shown success winning IDC contracts concentrated mainly on a singular customer focused portfolio.
The Federal Government competes and awards an Indefinite Delivery Contract (IDC) to support requirements where the quantity and time of delivery are unknown. Typically referred to as Indefinite Delivery-Indefinite Quantity (IDIQ) contracts, the Government has the option of awarding a single or multiple award IDIQ. Once awarded, an IDIQ acts as a master agreement between the Federal Government and one or more contractors. On an as-needed basis, Federal buying organizations place orders, commonly referred to as Task Orders against an IDIQ, to purchase goods or services available through the IDIQ.
- Contract Number
- SPE2DB22D1200
- Contractor
- AMERISOURCEBERGEN DRUG CORPORATION
- Obligations to Date
- $34.7M
- Ceiling Value
- $1,000M
- Award Date
- 03/23/2022
- Contract Type
- IDC
- Competition Set Aside Type
- No set aside used
- Buying Agency/Office
- Defense»Defense Logistics Agency (DLA)»DLA Troop Support»DLA Medical Directorate
Win More Federal Business
Imagine a world where every report, every insight is tailored specifically to you. Our entire platform is configured around your past performance so that everything is relevant.
All the Right Tools
Business Development & Pipeline Management
We start with the largest federal opportunity database, including forecasts and re-competes, and add layer a suite of pipeline management tools.
Personalized Markets
Our market-centric platform adds context to every pursuit. Every opportunity, every report, tailored specifically to you.
Award Research & Market Intelligence
Find gaps in the market, identify key competitors and teaming partners, evaluate performance, and analyze pathways to new business.
Start Your Free Account Today
Gain Full Access to This Report and...
Contract Opportunities
Pipeline Management
Award Research
Funding Analysis
Partner Identification
Industry and Market Intel
Agency Spending Trends
Competitive Insights
Federal Compass is software designed for today’s federal market.
Explore how the right intel and process can help lead your team to greater success.
Enjoy instant access to the Federal Compass platform
Task Order History
| Task Order No. | Contractor | Obligations | Effective Date |
|---|---|---|---|
| SPE2DB22FM8QM | AMERISOURCEBERGEN DRUG CORPORATION | $5.2k | 05/03/2022 |
| SPE2DB22FM8QL | AMERISOURCEBERGEN DRUG CORPORATION | $95.46 | 05/03/2022 |
| SPE2DB22FM8QD | AMERISOURCEBERGEN DRUG CORPORATION | $339.52 | 05/03/2022 |
| SPE2DB22FM8QQ | AMERISOURCEBERGEN DRUG CORPORATION | $9.6k | 05/03/2022 |
| SPE2DB22FM8QK | AMERISOURCEBERGEN DRUG CORPORATION | $3.15 | 05/03/2022 |
| SPE2DB22FM8QE | AMERISOURCEBERGEN DRUG CORPORATION | $96.80 | 05/03/2022 |
| SPE2DB22FM8QG | AMERISOURCEBERGEN DRUG CORPORATION | $14.8k | 05/03/2022 |
| SPE2DB22FM8QF | AMERISOURCEBERGEN DRUG CORPORATION | $29.04 | 05/03/2022 |
| SPE2DB22FM8QN | AMERISOURCEBERGEN DRUG CORPORATION | $20k | 05/03/2022 |
| SPE2DB22FM8QJ | AMERISOURCEBERGEN DRUG CORPORATION | $234.36 | 05/03/2022 |
| SPE2DB22FM8QP | AMERISOURCEBERGEN DRUG CORPORATION | $324.00 | 05/03/2022 |
| SPE2DB22FM8QH | AMERISOURCEBERGEN DRUG CORPORATION | $1.8k | 05/03/2022 |
| SPE2DB22FM8QR | AMERISOURCEBERGEN DRUG CORPORATION | $242.18 | 05/04/2022 |
| SPE2DB22FM8RD | AMERISOURCEBERGEN DRUG CORPORATION | $3.2k | 05/04/2022 |
| SPE2DB22FM8QW | AMERISOURCEBERGEN DRUG CORPORATION | $37.4k | 05/04/2022 |
| SPE2DB22FM8QV | AMERISOURCEBERGEN DRUG CORPORATION | $1.4k | 05/04/2022 |
| SPE2DB22FM8QX | AMERISOURCEBERGEN DRUG CORPORATION | $324.12 | 05/04/2022 |
| SPE2DB22FM8QY | AMERISOURCEBERGEN DRUG CORPORATION | $9.2k | 05/04/2022 |
| SPE2DB22FM8QU | AMERISOURCEBERGEN DRUG CORPORATION | $1.7k | 05/04/2022 |
| SPE2DB22FM8QZ | AMERISOURCEBERGEN DRUG CORPORATION | $1.9k | 05/04/2022 |
